Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. (2012)

First Author: Mander AP
Attributed to:  Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/pst.501

PubMed Identifier: 22232071

Publication URI: http://europepmc.org/abstract/MED/22232071

Type: Journal Article/Review

Volume: 11

Parent Publication: Pharmaceutical statistics

Issue: 2

ISSN: 1539-1604